論文

国際誌
2020年12月14日

ANGIOGRAPHIC RISK FACTORS FOR RECURRENCE OF MACULAR EDEMA ASSOCIATED WITH BRANCH RETINAL VEIN OCCLUSION.

Retina (Philadelphia, Pa.)
  • Takahiro Kogo
  • ,
  • Yuki Muraoka
  • ,
  • Akihito Uji
  • ,
  • Sotaro Ooto
  • ,
  • Tomoaki Murakami
  • ,
  • Shin Kadomoto
  • ,
  • Yuko Iida-Miwa
  • ,
  • Masahiro Miyake
  • ,
  • Manabu Miyata
  • ,
  • Akitaka Tsujikawa

記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1097/IAE.0000000000003026

PURPOSE: To examine angiographic risk factors for recurrence of macular edema (ME) associated with branch retinal vein occlusion (BRVO) METHODS:: We consecutively included 51 patients with treatment-naïve BRVO involving the macular area. Each eye initially received three monthly ranibizumab injections, with additional injections as necessary. At month 3, we examined parafoveal vessel diameter indexes (VDI) in all sectors using optical coherence tomography angiography and determined the association with retinal thickness changes (month 3 to month 5) and the number of ranibizumab injections during 12 months. RESULTS: Parafoveal VDIs in the affected, nasal, and temporal sectors at month 3 were significantly associated with corresponding parafoveal thickening (P=0.020, 0.010, and <0.001, respectively), and the parafoveal VDIs in the affected, and temporal sectors were significantly associated with future foveal thickening (P=0.037, and 0.026, respectively). Moreover, the parafoveal VDI in the temporal sector showed a significant association with the total required number of ranibizumab injections (P=0.040). CONCLUSION: The parafoveal VDI may adequately represent the degree of congestion associated with BRVO. Particularly, the VDI in the temporal sector may be a good predictor of future retinal thickening in the corresponding parafovea and the fovea and the number of ranibizumab injections.

リンク情報
DOI
https://doi.org/10.1097/IAE.0000000000003026
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33323902

エクスポート
BibTeX RIS